Advertisement

Loading...

Shanghai Henlius Biotech, Inc.

2696.HKHKSE
Healthcare
Biotechnology
HK$76.75
HK$7.00(10.04%)
Hong Kong Market is Open • 11:48

Shanghai Henlius Biotech, Inc. Fundamental Analysis

Shanghai Henlius Biotech, Inc. (2696.HK) shows moderate financial fundamentals with a PE ratio of 59.53, profit margin of 14.09%, and ROE of 18.53%. The company generates $4.3B in annual revenue with moderate year-over-year growth of 6.11%.

Key Strengths

PEG Ratio0.68

Areas of Concern

Cash Position2.36%
Current Ratio0.68
We analyze 2696.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 49.1/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
49.1/100

We analyze 2696.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

2696.HK struggles to generate sufficient returns from assets.

ROA > 10%
5.26%

Valuation Score

Moderate

2696.HK shows balanced valuation metrics.

PE < 25
59.53
PEG Ratio < 2
0.68

Growth Score

Excellent

2696.HK delivers strong and consistent growth momentum.

Revenue Growth > 5%
6.11%
EPS Growth > 10%
51.00%

Financial Health Score

Weak

2696.HK carries high financial risk with limited liquidity.

Debt/Equity < 1
1.08
Current Ratio > 1
0.68

Profitability Score

Moderate

2696.HK maintains healthy but balanced margins.

ROE > 15%
18.53%
Net Margin ≥ 15%
14.09%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is 2696.HK Expensive or Cheap?

P/E Ratio

2696.HK trades at 59.53 times earnings. This suggests a premium valuation.

59.53

PEG Ratio

When adjusting for growth, 2696.HK's PEG of 0.68 indicates potential undervaluation.

0.68

Price to Book

The market values Shanghai Henlius Biotech, Inc. at 10.61 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

10.61

EV/EBITDA

Enterprise value stands at 38.94 times EBITDA. This signals the market has high growth expectations.

38.94

How Well Does 2696.HK Make Money?

Net Profit Margin

For every $100 in sales, Shanghai Henlius Biotech, Inc. keeps $14.09 as profit after all expenses.

14.09%

Operating Margin

Core operations generate 14.84 in profit for every $100 in revenue, before interest and taxes.

14.84%

ROE

Management delivers $18.53 in profit for every $100 of shareholder equity.

18.53%

ROA

Shanghai Henlius Biotech, Inc. generates $5.26 in profit for every $100 in assets, demonstrating efficient asset deployment.

5.26%

Following the Money - Real Cash Generation

Operating Cash Flow

Shanghai Henlius Biotech, Inc. produces operating cash flow of $495.31M, showing steady but balanced cash generation.

$495.31M

Free Cash Flow

Shanghai Henlius Biotech, Inc. generates strong free cash flow of $465.15M, providing ample flexibility for dividends, buybacks, or growth.

$465.15M

FCF Per Share

Each share generates $0.86 in free cash annually.

$0.86

FCF Yield

2696.HK converts 1.29% of its market value into free cash.

1.29%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

59.53

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.68

vs 25 benchmark

P/B Ratio

Price to book value ratio

10.61

vs 25 benchmark

P/S Ratio

Price to sales ratio

8.39

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.68

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.19

vs 25 benchmark

ROA

Return on assets percentage

0.05

vs 25 benchmark

ROCE

Return on capital employed

0.09

vs 25 benchmark

How 2696.HK Stacks Against Its Sector Peers

Metric2696.HK ValueSector AveragePerformance
P/E Ratio59.5328.31 Worse (Expensive)
ROE18.53%699.00% Weak
Net Margin14.09%-130884.00% (disorted) Strong
Debt/Equity1.080.34 Weak (High Leverage)
Current Ratio0.682775.16 Weak Liquidity
ROA5.26%-14469.00% (disorted) Weak

2696.HK outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Shanghai Henlius Biotech, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

5658.77%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

185.73%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

356.36%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ